Sugi Predict

Sugi Predict / Compounds / SCHEMBL6074658

SCHEMBL6074658

SCHEMBL6074658

CSc1ncc2cc(Cl)c(Cl)nc2n1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.44
▸ KMT2A Q03164 4/20 0.44
▸ MAPT P10636 3/20 0.35
▸ LMNA P02545 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ HASPIN Q8TF76 1/20 0.34
▸ RPS6KA5 O75582 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ NPC1 O15118 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ AKT1 P31749 2/20 0.32
▸ AKT2 P31751 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29503599 1.00 MEN1 (0.44) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL6073377 0.83 MEN1 (0.38) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL6073354 0.83 MEN1 (0.38) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL29537852 0.83 MEN1 (0.38) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL3293161 0.83 MEN1 (0.41) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL30837295 0.79 MEN1 (0.36) MEN1KMT2AHASPINGAAHTT
SCHEMBL30837291 0.79 CYP1A2 (0.43) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL25272744 0.79 AURKA (0.46) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL19817044 0.79 FGFR1 (0.50) MEN1KMT2AAKT1AKT2
SCHEMBL29536567 0.79 AURKA (0.46) MEN1KMT2AMAPTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303540-A1 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME LLC (US) 2023-09-28 — — US disclosed
US-20230303540-A1 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME LLC (US) 2023-09-28 — — US disclosed
WO-2022051337-A1 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME CORP. (US) 2022-03-10 — — WO disclosed
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 — — US disclosed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 — — US disclosed
EP-1254137-A1 PYRIDO 2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2002-11-06 — — EP disclosed
WO-2001055147-A1 PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-08-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303540-A1 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF LRRK2, CLK2, BRSK2 MEN1 4150/4885KMT2A 736/4885MAPT 528/4885
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors CDK9, CDK19, CDK3 MEN1 4797/4885KMT2A 2672/4885MAPT 4678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.